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Objective: To assess shares of reimbursed orphan drugs and agreement in
reimbursement decision-making in different European Union member states as well as
to define odds for reimbursement influenced by the presence of conditional approval or
exceptional circumstances granted by the European Medicines Agency (EMA) or by type
of the disease.
Methods: The list of authorized drugs with current orphan designations was
collected from the website of the EMA. For each drug, the information regarding
conditional approval or approval under exceptional circumstances was collected. The
reimbursement statuses were available on national reimbursement or HTA agencies
websites. The agreement for reimbursement decisions between selected countries was
assessed using the κ coefficient for the measurement of agreement. The impact of the
EMA’s conditional approval as well as approval under exceptional circumstances was
assessed using the logistic regression and presented as odds ratio.
Results: The percentage of reimbursed orphan drugs varied significantly from 27%
in Poland to 88% in Denmark, with an average value of 51% (p < 0.0001). Regarding
the reimbursement status, the highest, substantial agreement was observed between
Spain and Italy, and the lowest agreement was observed between Germany and
England, with κ of 0.64 and 0.01, respectively. Conditional approval status significantly
decreased the chance for reimbursement in France, Italy, and Spain by 77–80%;
however, approval granted under exceptional circumstances had significant impact only
in Germany with 85% decrease in chances for reimbursement. The type of the disease
(oncology or metabolic) was significantly associated with both conditional approval (p
of 0.03—oncology drugs were more likely to be conditionally approved then the rest of
analyzed drugs) and exceptional circumstances (p of 0.02—drugs for metabolic diseases
were more likely to be approved under exceptional circumstances).
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Conclusions: Access to reimbursed orphan drugs varies significantly across EU
countries. The highest, substantial agreement in reimbursement decisions was observed
between Italy and Spain and the lowest between Germany and England. Conditional
approval and approval under exceptional circumstances were significant negative
predictors of reimbursement in some countries and they were significantly associated
with the type of the disease (oncology or metabolic).
Keywords: EMA (EuropeanMedicines Agency), orphan drugs for rare diseases, reimbursement, authorization, HTA
(Health Technology Assessment)
BACKGROUND
There is no common definition of an orphan drug, which is
the reason for discrepancies among the definitions implemented
by different countries in their drug reimbursement decision-
making process. However, there is general acceptance that the
definition should be based on the prevalence of rare diseases
treated by orphan drugs. According to the current definition
provided by the European Union (EU), rare diseases mostly
include inherited, life-threatening, or chronically debilitating
diseases that affect fewer than 5 out of 10,000 people (EMEA,
2017). The assumed threshold prevalence varied from 1 to 8 per
10,000 people (Winstone et al., 2015). According to the definition
by the European Medicines Agency’s (EMA), the prevalence
is 5 persons per 10,000, which translates into around 246,000
people affected by rare diseases, considering 27 EUmember states
(Winstone et al., 2015; EMEA, 2017).
Different types of rare diseases can be defined and the broadest
categories include oncologic diseases (around 32.5% of all orphan
drugs; Gammie et al., 2015) and metabolic conditions. As orphan
diseases have mostly genetic origin both oncologic and metabolic
orphan drugs are of special interest for EMA.
In order for a drug to fulfill the EMA’s conditions of orphan
drugs, it needs to be used for the diagnosis, prevention, or
treatment of patients with a life-threatening or chronically
debilitating condition. The EMA’s definition includes also drugs
that are unlikely to generate sufficient profit to justify research
and development costs (Winstone et al., 2015; EMEA, 2017).
This doubtful and uncertain return on the investment makes
the health technology assessment (HTA) process very difficult
and challenging because the required data on clinical efficacy
and safety as well as data pertaining to costs may simply
be insufficient. What makes the reimbursement decision even
harder is the fact that orphan drugs are generally more expensive
than non-orphan drugs due to frequent genetic etiology of the
targeted disease (EMEA, 2017), which translates into significant
budget impact despite a low number of potential patients. It
is an important aspect of proper allocation of public finances
presenting a major problem for public health and decision-
making. This fact may be reflected in substantial variation of
reimbursement decisions for orphan drugs among EU state
members.
Orphanet (https://www.orpha.net/consor/cgi-bin/index.php)
is a reference portal with information on rare diseases and
orphan drugs for all audiences. Its goal is to gather and improve
knowledge on rare diseases, their diagnosis, and nomenclature
as well as care and treatment of patients with these diseases
(Orphanet, 2018).
To help national decision-makers as well as national HTA
agencies, the EMA issues a conditional marketing authorization
(also known as a conditional approval) indicating that the
medicine is addressed to fulfill important and unmet treatment
needs of patients (which is often the case in patients with rare
diseases). The data for the approval are less comprehensive
than normally required. The presented data, however, are
demanded to indicate that potential benefits from applying
the treatment are higher than potential losses (risks). The
marketing authorization holder is then obligated to provide
a comprehensive body of clinical evidence in the future,
usually within a time frame negotiated with the EMA. This
conditional approval could be a signal for national decision-
makers that comprehensive data will be available (EMA,
2017).
However, in some cases the condition to be treated is
rare or the collection of detailed information is impossible
or unethical. In these situations, the EMA may grant a
marketing authorization in absence of comprehensive data under
exceptional circumstances. It is a type of marketing authorization
granted to medicines of which the marketing authorization
holder is unable (and will probably never be able) to provide
comprehensive data on the efficacy and safety under normal
conditions of use.
Unlike conditional marketing authorization, in which
marketing approval is granted in the likelihood that the
sponsor will provide such data within an agreed time frame,
authorization under exceptional circumstances can be granted
when comprehensive data cannot be obtained even after
authorization. This could be an important signal for national
decision-makers and could potentially influence their decision,
especially in a situation of a very limited budget (Commission
Regulation, 2006).
Our objective was to assess the share of reimbursed
orphan drugs as well as the agreement in reimbursement
decision-making in different EU member states; we would
like to evaluate if reimbursement decisions are influenced
by the presence of conditional approval or exceptional
circumstances granted by EMA. In addition the impact
of type of disease (oncologic or metabolic) on conditional
approval and approval under exceptional circumstances was
examined.
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METHODS
The list of authorized drugs with current orphan designations
was collected from the EMAwebsite (on 24 January 2017) (EMA,
2018). A list of countries that had databases of reimbursed
drugs publicly available and that allowed for such an analysis
to be performed was composed. The reimbursement status
of each drug was collected for Belgium, Denmark, England,
France, Germany, Italy, Poland, Scotland, Spain, Sweden, The
Netherlands, and Wales (Tables 1, 2). To perform sophisticated
and in-depth analysis, data on recommendations were also
collected for selected countries. The links to national websites
TABLE 1 | Review of pricing strategies and reimbursement decision making process for orphan drugs in different European countries (Panteli et al., 2016).
Country Pricing Managed entry agreements Reimbursement requirements and
decision-making—other remarks
Belgium • External reference pricing
• Internal reference pricing
• Value-based pricing
• Negotiations
Financial arrangement Belgium is a member of BeNeLuxA initiative (BeNeLuxA
Initiative, 2018). For orphan drugs a budget impact analysis is
required in the reimbursement dossier but a
cost-effectiveness analysis is not. In addition, the
reimbursement dossiers are not publicly available (Denis
et al., 2011)(Picavet et al., 2014).
Denmark • Internal reference pricing
• Competition (retail)
• Tendering (hospitals)
Financial arrangement
Linked to optimizing
Utilization
Reimbursement decisions are based on therapeutic effect,
value added, and safety profile. In addition, the price
comparisons and economic analyzes are also required in the
decision-making process. The Danish Medicines Agency (a
board that runs parallel to National Board of Health under the
Danish Ministry of Health) decides on the reimbursement
status of each drug. In addition, the Reimbursement
Committee makes the recommendations and advises Danish
Medicines Agency before they make any decision on whether
or not to reimburse a particular drug (Møller Pedersen, 2003;
Olejaz et al., 2012).
England,
Scotland, Wales
• Value-based pricing
• Negotiations
• Profit margins
Financial arrangement, financial
arrangement
Linked to optimizing
Utilization and primarily evidence
Generation
The Rare Diseases Advisory Group exists in NHS England,
NHS Scotland, NHS Wales, and NHS Northern Ireland in
order to make recommendations developing and
implementing the strategy for rare diseases and highly
specialized services (RDAG, 2018).
France • External reference pricing
• Internal reference pricing
• Value-based pricing
• Negotiations
Financial arrangement Orphan drugs undergo the same HTA, pricing, and
reimbursement procedures as the other drugs (Young et al.,
2017).
Germany • External reference pricing
• Internal reference pricing
• Value-based pricing
Financial arrangement and financial
arrangement
Linked to optimizing
Utilization
Orphan drugs undergo the same, pricing and reimbursement
procedures as the other drugs. Benefits of particular
treatments are considered proven when the drug is
authorized (Young et al., 2017).
Italy • External reference pricing
• Internal reference pricing
• Value-based pricing
• Negotiations
Financial arrangement and financial
arrangement
Linked to optimizing
Utilization
Orphan drugs undergo the same HTA and reimbursement
procedures as the other drugs. The pricing of orphan drugs
benefits from more relaxed regulations and accepted levels of
uncertainty (Young et al., 2017).
Poland • External reference pricing
• Internal reference pricing
• Value-based pricing
• Negotiations
Financial arrangement Orphan drugs undergo the same HTA, pricing, and
reimbursement procedures as the other drugs (Tordrup et al.,
2014).
Spain • External reference pricing
• Internal reference pricing
Financial arrangement and financial
arrangement
Linked to optimizing
Utilization
Orphan drugs undergo the same HTA, pricing, and
reimbursement procedures as the other drugs (Young et al.,
2017).
Sweden • Internal reference pricing
• Value-based pricing
• Tendering
Financial arrangement and financial
arrangement
Linked to optimizing
Utilization
Orphan drugs undergo the same pricing and reimbursement
procedures as the other drugs. The HTA process can accept
more relaxed assumptions (Young et al., 2017).
The Netherlands • External reference pricing
• Internal reference pricing
• Negotiations
Primarily evidence
Generation
Negotiations are confidential and applied only to orphan
drugs (Panteli et al., 2016).
HTA, health technology assessment; NHS, National Health Service.
Frontiers in Pharmacology | www.frontiersin.org 3 November 2018 | Volume 9 | Article 1263
Malinowski et al. Orphan Drugs in Europe
TABLE 2 | Reimbursement status of analyzed orphan drugs in selected countries.
Medicine name Belgium Denmark England France Germany Italy Poland Scotland Spain Sweden The netherlands Wales
Adcetris 3 3 3 7 3 3 3 3 3 3 7 3
Adempas 3 3 3 3 3 3 3 3 3 3 3 3
Alprolix 3 3 3 7 3 7 7 7 7 7 3 7
Arzerra 7 3 3 7 3 3 7 3 3 3 3 7
Atriance 3 3 3 7 3 3 3 3 3 7 7 3
Blincyto 7 3 7 7 3 7 7 3 7 7 7 3
Bosulif 3 3 3 3 3 3 3 3 3 3 3 3
Bronchitol 7 3 3 7 3 7 7 3 7 7 7 7
Carbaglu 3 3 3 3 3 3 7 3 3 3 3 7
Cayston 3 3 3 3 3 7 7 3 3 3 3 3
Ceplene 7 3 7 3 3 7 7 7 7 3 7 7
Cerdelga 3 3 3 3 3 7 7 7 3 7 7 7
Coagadex 7 7 3 7 7 7 7 7 7 7 7 7
Cometriq 7 3 3 7 3 7 7 7 7 3 3 3
Cresemba 7 3 3 3 3 3 7 3 3 7 3 3
Cystadane 3 3 3 3 3 7 3 3 3 3 3 7
Dacogen 3 3 3 7 3 3 7 7 3 7 3 7
Darzalex 3 3 7 7 3 7 7 7 3 7 7 7
Defitelio 7 3 3 7 7 7 7 3 7 7 3 3
Deltyba 7 7 3 3 3 7 7 7 7 7 7 7
Diacomit 3 3 3 3 3 3 3 3 3 3 3 3
Elaprase 3 3 3 7 3 3 3 7 3 7 7 7
Esbriet 3 3 3 3 3 3 3 3 3 3 3 7
Farydak 3 3 3 7 3 7 7 3 7 7 3 7
Firazyr 3 3 3 3 3 3 3 3 3 3 7 3
Firdapsea 7 3 3 3 3 7 7 3 7 7 3 7
Galafold 3 3 3 3 3 7 7 3 7 3 7 3
Gazyvaro 3 3 3 7 3 7 3 3 3 7 3 7
Gliolan 3 3 7 7 3 7 7 7 3 7 7 7
Glybera 7 7 3 7 7 7 7 7 7 7 7 7
Granupasb 7 3 3 3 3 7 7 7 7 7 7 7
Hetlioz 7 7 7 7 3 7 7 7 7 7 7 7
Holoclar 3 3 3 7 7 7 7 7 7 7 3 7
Iclusig 3 3 3 3 3 3 7 3 3 3 3 3
Idelvion 3 3 3 7 7 7 7 7 7 7 3 7
Imbruvica 3 3 3 3 3 3 3 3 3 3 3 3
Imnovidc 3 3 3 3 3 3 7 3 3 3 3 3
Increlex 3 3 3 3 3 3 3 3 3 3 3 3
Inovelon 3 3 7 3 3 3 7 3 3 3 3 3
Kalydeco 3 3 3 3 7 3 7 7 3 7 3 3
Kanuma 7 3 3 7 7 7 7 7 7 7 7 7
Ketoconazole HRA 7 3 3 3 3 7 7 7 7 3 7 7
Kolbam 7 7 3 7 7 7 7 7 7 7 7 7
Kuvan 3 3 3 3 3 3 7 7 3 7 3 7
Kyprolis 3 3 7 7 3 3 7 7 3 7 7 7
Lartruvo 7 3 7 7 3 7 7 7 3 7 7 7
Lenvima 7 3 7 3 3 3 7 3 3 7 3 7
Lynparza 3 3 3 7 3 3 3 3 3 7 3 7
Mepact 7 3 7 3 3 3 7 3 3 7 7 7
Mozobil 3 3 3 3 3 3 3 3 3 7 7 3
Nexavar 3 3 3 3 3 3 3 3 3 7 3 3
(Continued)
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TABLE 2 | Continued
Medicine name Belgium Denmark England France Germany Italy Poland Scotland Spain Sweden The netherlands Wales
NexoBrid 3 3 7 7 3 3 7 7 7 7 7 7
Ninlaro 3 3 3 7 3 7 7 7 7 7 7 7
Nplate 3 3 7 3 3 3 7 3 3 7 3 7
Ocaliva 7 3 3 3 3 7 7 3 7 7 7 7
Ofev 3 3 3 3 3 3 7 3 3 7 3 7
Onivyde 7 3 7 7 3 7 7 7 7 7 7 7
Opsumit 3 3 3 3 3 3 3 3 3 3 3 3
Orphacol 7 3 3 3 3 7 7 7 3 7 3 7
Peyonad 7 3 7 7 3 7 7 7 3 7 7 7
Plenadren 7 3 7 7 3 3 7 3 7 7 7 7
Procysbi 7 3 3 3 3 7 7 7 7 7 7 7
Ravicti 7 3 3 7 3 7 7 7 7 7 7 7
Raxone 7 3 3 7 3 7 7 3 7 3 3 7
Revestive 7 3 3 3 3 7 7 7 3 7 7 7
Revlimid 3 3 3 3 3 3 3 3 3 3 3 3
Scenesse 7 7 7 7 7 7 7 7 7 7 7 7
Signifor 7 3 7 3 3 3 7 3 3 3 3 3
Siklos 3 7 3 3 3 7 7 3 3 7 3 7
Sirturo 7 3 3 7 3 3 7 7 7 7 3 3
Soliris 3 3 3 7 3 3 7 7 3 7 7 3
Sprycel 3 3 3 3 3 3 3 3 3 3 3 3
Strensiq 7 3 3 7 7 7 7 7 7 7 7 7
Strimvelis 7 7 7 7 7 7 7 7 7 7 3 7
Sylvant 7 3 7 7 3 3 7 7 3 7 3 7
Tasigna 3 3 3 3 3 3 3 3 3 3 3 7
Tepadina 3 3 7 7 3 3 3 7 3 7 7 7
Thalidomide
Celgenee
3 3 3 3 3 7 7 7 7 3 3 3
Tobi Podhaler 3 3 3 3 3 7 7 3 7 7 3 7
Torisel 3 3 3 7 3 3 3 7 3 7 7 7
Translarna 7 3 3 7 7 7 7 7 7 7 7 3
Unituxin 7 7 7 7 3 7 7 7 7 7 7 7
Venclyxto 7 3 7 7 3 7 7 7 7 7 3 7
Vidaza 3 3 3 3 3 3 3 3 3 7 3 7
Vimizim 7 3 3 7 3 3 7 7 7 7 7 3
Volibris 3 3 3 3 3 3 3 3 3 3 3 3
Votubia 3 3 3 3 3 3 3 7 3 3 3 7
Vpriv 3 3 3 3 3 3 3 3 3 7 3 3
Vyndaqel 3 3 7 3 7 3 7 7 3 7 3 7
Wakix 7 7 7 3 3 7 7 7 7 7 7 7
Xagrid 3 3 3 3 3 3 3 3 3 3 3 3
Xaluprinef 7 3 7 3 3 7 7 3 3 3 3 3
Yondelis 3 3 3 7 3 3 3 7 3 7 7 7
Zalmoxis 7 7 7 7 7 7 7 7 7 7 7 7
Zavesca 3 3 3 3 3 3 7 3 3 3 3 7
number of positive
decisions
54 84 69 50 81 47 26 47 56 30 52 29
number of
negative decisions
41 11 26 45 14 48 69 48 39 65 43 66
3, reimbursement; 7, no reimbursement.
aPreviously Zenas.
bPreviously Para-aminosalicylic acid Lucane.
cPreviously Pomalidomide Celgene.
dPreviously Nymusa.
ePreviously Thalidomide Pharmion.
fPreviously Mercaptopurine Nova Laboratories.
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accessed for data collection are presented in the Appendix. For
each drug, the information regarding conditional approval or
approval under exceptional circumstances was collected from
the EMA’s website. Then the review of Orphanet database was
performed for each drug and corresponding disease targeted
FIGURE 1 | The percentage of reimbursed orphan drugs in selected countries.
by the drug, what revealed that most of orphan drugs were
authorized for the treatment of patients with oncologic or
metabolic diseases. For that reason, additional analyzes were
performed for relevant subgroups of drugs dedicated to the
treatment of patients with oncology or metabolic conditions,
and a comparison of the results between these 2 subgroups
and drugs used for treatment of patients with other diseases
(neither oncologic nor metabolic) was made. We focused on
drugs for oncologic or metabolic conditions as they are large
groups of orphan drugs so justify statistical analysis. Less
prevalent groups could be analyzed only descriptively (EMA,
2018).
Significant differences between reimbursement systems
among the countries can impact the comparisons and agreement
in recommendations and reimbursement status for the
analyzed drugs. The agreement between recommendations
and reimbursement decisions for each country separately as well
as between countries were assessed using the κ coefficient for
measurement of agreement, with values lower than 0 denoting
less than chance agreement; between 0.01 and 0.20, slight
agreement; between 0.21 and 0.40, fair agreement; between
0.41 and 0.60, moderate agreement; between 0.61 and 0.80,
substantial agreement; and between 0.81 and 0.99, almost perfect
TABLE 3 | The relation in reimbursement decisions and type of a disease in selected countries.
Country Reimbursement Metabolic diseases Oncologic diseases Other diseases Total p-value (χ2-test)
Belgium Not reimbursed 12 (54.55%) 12 (33.33%) 17 (45.95%) 41 0.2597
Reimbursed 10 (45.45%) 24 (66.67%) 20 (54.05%) 54
Denmark Not reimbursed 4 (18.18%) 2 (5.56%) 5 (13.51%) 11 0.2881
Reimbursed 18 (81.82%) 34 (94.44%) 32 (86.49%) 84
England Not reimbursed 3 (13.64%) 14 (38.89%) 9 (24.32%) 26 0.0971
Reimbursed 19 (86.36%) 22 (61.11%) 28 (75.68%) 69
France Not reimbursed 10 (45.45%) 21 (58.33%) 14 (37.84%) 45 0.2105
Reimbursed 12 (54.55%) 15 (41.67%) 23 (62.16%) 50
Germany Not reimbursed 7 (31.82%) 1 (2.78%) 6 (16.22%) 14 0.0097*
Reimbursed 15 (68.18%) 35 (97.22%) 31 (83.78%) 81
Italy Not reimbursed 12 (54.55%) 15 (41.67%) 21 (56.76%) 48 0.3971
Reimbursed 10 (45.45%) 21 (58.33%) 16 (43.24%) 47
Poland Not reimbursed 18 (81.82%) 21 (58.33%) 30 (81.08%) 69 0.0507
Reimbursed 4 (18.18%) 15 (41.67%) 7 (18.92%) 26
Scotland Not reimbursed 14 (63.64%) 17 (47.22%) 17 (45.95%) 48 0.3715
Reimbursed 8 (36.36%) 19 (52.78%) 20 (54.05%) 47
Spain Not reimbursed 11 (50.00%) 10 (27.78%) 18 (48.65%) 39 0.1205
Reimbursed 11 (50.00%) 26 (72.22%) 19 (51.35%) 56
Sweden Not reimbursed 15 (68.18%) 22 (61.11%) 28 (75.68%) 65 0.4082
Reimbursed 7 (31.82%) 14 (38.89%) 9 (24.32%) 30
The Netherlands Not reimbursed 13 (59.09%) 16 (44.44%) 14 (37.84%) 43 0.2821
Reimbursed 9 (40.91%) 20 (55.56%) 23 (62.16%) 52
Wales Not reimbursed 16 (72.73%) 26 (72.22%) 24 (64.86%) 66 0.7376
Reimbursed 6 (27.27%) 10 (27.78%) 13 (35.14%) 29
Total 22 36 37 95
*statistically significant.
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agreement (Viera and Garrett, 2005). All κ coefficients were
supported with 95% confidence intervals (CIs) and rounded to 2
decimal places.
The comparison of 2 nominal variables was performed using
the χ2-test or the Fisher exact test where applicable, depending
on expected cell counts in contingency tables. The results of the
TABLE 5 | Relation between reimbursement status and conditional approval.
Country Conditional approval p-value (χ2-test)
No Yes
Not reimbursed Reimbursed Not reimbursed Reimbursed
Belgium 32 (39.51%) 49 (60.49%) 9 (64.29%) 5 (35.71%) 0.0839
Denmark 9 (11.11%) 72 (88.89%) 2 (14.29%) 12 (85.71%) 0.7318
England 21 (25.93%) 60 (74.07%) 5 (35.71%) 9 (64.29%) 0.4481
France 34 (41.98%) 47 (58.02%) 11 (78.57%) 3 (21.43%) 0.0113*
Germany 11 (13.58%) 70 (86.42%) 3 (21.43%) 11 (78.57%) 0.4443
Italy 37 (45.68%) 44 (54.32%) 11 (78.57%) 3 (21.43%) 0.0230*
Poland 57 (70.37%) 24 (29.63%) 12 (85.71%) 2 (14.29%) 0.2344
Scotland 38 (46.91%) 43 (53.09%) 10 (71.43%) 4 (28.57%) 0.0903
Spain 29 (35.80%) 52 (64.20%) 10 (71.43%) 4 (28.57%) 0.0123*
Sweden 54 (66.67%) 27 (33.33%) 11 (78.57%) 3 (21.43%) 0.3762
The Netherlands 34 (41.98%) 47 (58.02%) 9 (64.29%) 5 (35.71%) 0.1215
Wales 57 (70.37%) 24 (29.63%) 9 (64.29%) 5 (35.71%) 0.6480
*, Bold values—Statistically significant.
TABLE 6 | Relation between reimbursement status and approval under exceptional circumstances.
Country Approval under exceptional circumstances p-value (χ2-test)
No Yes
Not reimbursed Reimbursed Not reimbursed Reimbursed
Belgium 32 (39.51%) 49 (60.49%) 9 (64.29%) 5 (35.71%) 0.0839
Denmark 8 (9.88%) 73 (90.12%) 3 (21.43%) 11 (78.57%) 0.2123
England 23 (28.40%) 58 (71.60%) 3 (21.43%) 11 (78.57%) 0.5893
France 37 (45.68%) 44 (54.32%) 8 (57.14%) 6 (42.86%) 0.4276
Germany 8 (9.88%) 73 (90.12%) 6 (42.86%) 8 (57.14%) 0.0013*
Italy 39 (48.15%) 42 (51.85%) 9 (64.29%) 5 (35.71%) 0.2648
Poland 58 (71.60%) 23 (28.40%) 11 (78.57%) 3 (21.43%) 0.5893
Scotland 40 (49.38%) 41 (50.62%) 8 (57.14%) 6 (42.86%) 0.5919
Spain 31 (38.27%) 50 (61.73%) 8 (57.14%) 6 (42.86%) 0.1850
Sweden 55 (67.90%) 26 (32.10%) 10 (71.43%) 4 (28.57%) 0.7932
The Netherlands 36 (44.44%) 45 (55.56%) 7 (50.00%) 7 (50.00%) 0.6998
Wales 56 (69.14%) 25 (30.86%) 10 (71.43%) 4 (28.57%) 0.8634
*, Bold values—Statistically significant.
TABLE 7 | Relation between conditional approval, approval under exceptional circumstances, and type of disease.
Disease type Conditional approval p-value Approval under exceptional circumstances p-value (χ2-test)
No Yes No Yes
Oncologic 27 (75%) 9 (25%) 0.0323* 34 (94.44%) 2 (5.56%) 0.0227*
Metabolic 22 (100%) 0 (0%) 15 (68.18%) 7 (31.82%)
Other 32 (86.49%) 5 (13.51%) 32 (86.49%) 5 (13.51%)
*Statistically significant.
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tests were presented as p-values rounded to 4 decimal places. The
data were summarized with counts and percentages.
The impact of the EMA’s conditional approval as well as
approval under exceptional circumstances was assessed using the
logistic regression and presented as odds ratio (OR) showing
the odds for reimbursement when these types of approval were
granted compared with no conditional approval or approval
under exceptional circumstances status. Logistic regression was
also used to investigate the impact of type of the disease on the
type of approval. All ORs were presented with 95% CI rounded
to 2 decimal places and corresponding p-values rounded to 4
decimal places. A p-value of <0.05 was considered statistically
significant. Statistical analyzes were carried out in the JMP R©
software, version 13.1.0 (SAS Institute Inc., 2016, Cary, North
Carolina 27513, USA).
RESULTS
Analysis of Reimbursement Decisions for
Orphans in Selected Countries
The reimbursement status was assessed for a total of 95 orphan
drugs in 12 countries. The percentage of reimbursed drugs varied
from 27% in Poland to 88% in Denmark (Figure 1). Considering
the type of a disease (metabolic/oncologic) a statistically
significant relation with the reimbursement status was observed
only in Germany (Table 3). Regarding the reimbursement status,
the highest, substantial agreement was observed between Spain
and Italy, and the lowest agreement was detected between
Germany and England, with κ of 0.64 and 0.01, respectively
(Table 4).
The Impact of Conditional Approval and
Approval Under Exceptional
Circumstances on Reimbursement Status
The conditional approval was associated with reimbursement
status only in France, Italy, and Spain. The EMA’s conditional
approval status in France decreased odds for reimbursement
FIGURE 2 | The percentage of positive reimbursement recommendations.
by 80% (OR, 0.20; 95% CI, 0.05–0.76; p = 0.0185), in Italy by
77% (OR, 0.23, 95% CI, 0.06–0.88; p = 0.0324), and in Spain
by 78% (OR, 0.22; 95% CI, 0.06–0.77; p = 0.0182) (Table 5).
Approval under exceptional circumstances was associated with
the reimbursement status only in Germany, where the odds
for reimbursement were 85% (OR, 0.15; CI 95%, 0.04–0.53;
p = 0.0034) lower for drugs approved under exceptional
circumstances when compared with other drugs (Table 6).
The Impact of Type of Disease on
Conditional Approval and Approval Under
Exceptional Circumstances
Out of all drugs, 36 (38%) were used for treatment of patients
with oncologic diseases (e.g., relapsed or refractory CD30+
Hodgkin lymphoma), 22 (23%) for metabolic diseases (e.g., type
1 Gaucher disease), and 37 (39%) for other diseases (e.g., cystic
fibrosis, severe hepatic veno-occlusive disease). Both conditional
approval and approval under exceptional circumstances were
associated with the type of the disease. Almost one-third of
orphan drugs for metabolic diseases were granted approval under
the exceptional circumstances compared with only 6% in the
case of drugs for oncologic diseases; however, in the case of
conditional approval the situation was reversed: a quarter of
orphan drugs for oncologic diseases was approved conditionally,
compared with 0% of orphan drugs for metabolic diseases
(Table 7).
Drugs for metabolic diseases were 8.25-fold (95% CI, 1.6–
46.90; p = 0.0123) more likely to be approved under exceptional
circumstances, but had 96% less odds for being conditionally
approved (OR, 0.04; 95% CI, 0.00006–0.67; p = 0.0092) when
compared to other drugs for non-metabolic and non-oncologic
diseases. The opposite was observed for drugs used in treatment
of patients with oncologic diseases. Those drugs were 87% less
likely to be approved under exceptional circumstances (OR, 0.83;
95% CI, 0.01–0.84; p = 0.0301) and had the odds for being
conditionally approved increased 10-fold (95% CI, 1.58–287.77;
p = 0.006) when compared with other drugs for non-metabolic
and non-oncologic diseases.
Additional Analysis of Recommendations
for Orphans in Selected Countries
To perform a sophisticated analysis of recommendations, we
made a review of officially available websites and databases and
collected relevant data. We found all necessary data only for
5 countries: Denmark, England, France, Poland, and Scotland.
The percentage of positive recommendations varied from 44% in
Poland to 92% in England (Figure 2).
The agreement in recommendation type (negative or positive)
was assessed between Denmark, England, France, Poland, and
Scotland. For these countries information about positive and
negative recommendations was available online. The highest
agreement was observed between England and Scotland (κ
of 0.54) and the lowest between England and Denmark
(insignificant κ of−0.04) (Table 8).
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TABLE 8 | The agreement in reimbursement recommendations between selected countries.
Country England France Poland Scotland
Denmark −0.04 (−0.11 to 0.02) 0.13 (−0.08 to 0.33) 0.00 (0.00 to 0.00) 0.06 (−0.05 to 0.17)
England 0.32 (−0.08 to 0.71) 0.17 (−0.05 to 0.40) 0.54 (0.16 to 0.91)
France 0.16 (−0.07 to 0.39) 0.12 (−0.11 to 0.35)
Poland 0.27 (0.03 to 0.51)
κ coefficients with 95% confidence intervals.
The observed agreement between recommendation and the
reimbursement status within countries varied from 0.09 (−0.25
to 0.44) in England to 0.7 (0.55–0.96) in Denmark (Figure 3).
DISCUSSION
The study investigated the shares of reimbursed orphan drugs
among all those with orphan designation among several EU
countries and the agreement between them. In addition, to
our best knowledge this is the first study that investigates the
impact of conditional approval and exceptional circumstances on
reimbursement decisions in EU countries.
In France, Italy, and Spain, conditional approval significantly
decreased the odds for reimbursement, which suggest that the
decision-making body in those countries waits for further data on
efficacy or safety (the EMA, after providing conditional approval,
requires the applicant to provide further data within the agreed
time frame) while in other considered countries the impact of
approval status was assessed although not significant. However,
a similar association was observed in terms of approval under
exceptional circumstances in Germany with the same impact.
The observed agreement in reimbursement decisions among the
countries varied from agreement on a random level to substantial
agreement.
The reimbursement status was significantly associated with
the type of the disease (metabolic or oncologic) only for Germany
(p < 0.01). Taking into account all considered countries the type
of disease was however significantly associated with the type of
authorization by EMA—drugs for metabolic diseases were 8.25-
fold more likely to be approved under exceptional circumstances,
oncologic drugs had the odds for being conditionally approved
increased 10-fold.
In response to increasing health expenditures, more and
more third-party payers tend to rationalize their expenses
by implementing cost-effectiveness criterion prior to pricing
and reimbursement decisions or at least by referencing
pharmaceutical prices of the countries in which evidence on cost-
effectiveness are mandated. Objective decision-making for public
reimbursement has to be based on clinical and economic criteria,
but social issues should also be considered. It is important to
note that this study analyzed mostly old (pre-2004) member
states of the European Union (EU15) and only one post-
2004 accession state (Poland). This may raise some concerns
because the comparison was between high-income and low-
income countries. However, the results of this study provide
a good basis for further research on this subject, especially
that the Central Eastern European region has expanded its
pharmaceutical share of health spending at an 8-fold higher
annual rate compared with EU15 (Jakovljevic et al., 2016). This
may result in a faster increase in the share of reimbursed
orphan drugs in post-2004 member states. This trend might be
then enhanced by new generic versions of orphan drugs that
should enter the pharmaceutical market shortly, because patent
protection and the exclusivity period for several orphan drugs
will expire soon. However, this could raise some concerns as this
substitution should be based not only on an economic analysis
but also on clinical and patient-reported outcomes (Di Paolo and
Arrigoni, 2018). This is particularly important because orphan
drugs together with targeted biologics are considered the most
expensive types of pharmaceuticals (Jakovljevic and Yamada,
2017).
Financial aspects are the major determinant of the observed
differences among the analyzed countries. Many countries apply
additional mechanisms to allow access to medicines for which
there is high uncertainty (at the time of marketing authorization)
regarding effectiveness, cost-effectiveness, or budget impact.
These mechanisms are commonly referred to as managed entry
agreements (MEAs), that is, negotiations between payers and
manufacturers to share the cost of uncertainty. The objective
of MEAs is to facilitate access to new and expensive medicines,
including orphan drugs.
Various approaches to pricing are another factor that
contributed to differences in the availability of orphan drugs.
Price revisions are conducted periodically or when necessary,
and this varies between countries. In Belgium and Germany,
regular revisions may concern only some groups of drugs. Those
revisions could be associated with negotiations between the payer
andmarketing authorization holder (as in France or Italy) or with
the planned review of reimbursement decisions after a specific
fixed period (as in Poland or the Netherlands) (Panteli et al.,
2016).
Drugs for metabolic diseases were more likely to be
approved under exceptional circumstances but less likely to
be conditionally approved compared with other orphan drugs.
This was due to inability to collect comprehensive data on
their efficacy and safety. Many drugs for metabolic diseases
come as enzyme-replacement therapies, the approval of which
may not require comprehensive data on safety. On the other
hand, oncologic orphan drugs were more often approved under
conditional marketing authorization to provide patients with
new drugs as fast as possible even if clinical data were immature
or incomplete. However, marketing authorizations holders are
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FIGURE 3 | The agreement between recommendations and reimbursement
status in the analyzed countries.
obliged to provide relevant data within a defined period to
maintain the registration status.
We performed a review on publications for current
reimbursement policies in European settings, however no
other studies investigated the influence of authorization details
on the reimbursement. We reviewed some papers published
lately that face the problems. The present study is innovative,
as we did not identify valid studies on the similar topic carried
out for European countries. A study by Kawalec et al. (2016)
had a similar approach, but a revision of methods and an
update of input data were necessary to provide the topical
and valid review on the management of orphan drugs in the
selected European countries. The study revealed that 21% of
EMA-authorized orphan drugs were reimbursed in 8 European
countries that were studied: 49% of those orphan drugs had
positive reimbursement recommendations, 54% of those had
conditional reimbursement recommendations, and 16% had
negative reimbursement recommendations. The shares of the
orphan drugs for oncologic diseases, orphan drugs for ultrarare
diseases and other orphan drugs that were assessed by HTA
agencies were similar, with the lowest percentage observed in
ultra-orphan drugs (72%) and the highest in other orphan drugs
(80%). While the highest rate of reimbursement was observed
among drugs with positive or conditional recommendation,
a high rate of reimbursement (11%) was revealed among
ultra-orphan drugs that had never been assessed by any HTA
agency (Kawalec et al., 2016). Although methods used in the
previous study by Kawalec et al. (2016) seem quite similar,
the results are unsuitable for direct comparisons. The orphan
drugs varied between this study and the previous one, since
in the period between the 2 studies some new drugs were
approved as orphans and some drugs failed to maintain the
status of orphan drugs. Consequently, a dataset on orphan
drugs differed significantly between the previous and present
study, which influenced the results and conclusions. In 2015, the
study focused on correlations between recommendations and
reimbursement decisions in selected countries, while present
study focused on the odds of agreement between countries and
the impact of special EMA approval modes (conditional approval
and approval under exceptional circumstances) on chances for
reimbursement.
The percentages of reimbursed orphan drugs were lower in
the present study than those observed in other studies (Garau
andMestre-Ferrandiz, 2009; Gammie et al., 2015); as we consider
the revealed differences were due different sets of orphan drugs
taken under consideration because 3 years ago partly another set
of orphan drugs was analyzed. That is why we observed 32% of
reimbursed orphan drugs compared to 69% for Sweden however
for Scotland the observed percentage of reimbursed orphans 49%
was similar to reported 54%.
A comparative analysis on the access to orphan drugs in a
sample of Balkan countries −5 EU member states (Bulgaria,
Croatia, Greece, Romania, Slovenia) and 2 EU candidate
countries (Serbia, Montenegro)—was carried out by Pejcic et al.
(2018). It revealed significant inequalities among these countries
as well as a substantial lack of access to orphan drugs approved for
EUmarket and a need for improvement in accessibility of orphan
drugs in the Balkan states.
Another study was carried out by Sarnola et al. (2018) to assess
reimbursement and pricing policies specific to orphan medicines
and the availability and distribution settings of 10 recently
authorized medicinal products in 24 European countries.
No specific policies were implemented in the assessment of
reimbursement status of orphan drugs in 22 countries, and in
20 countries no special policies were implemented for pricing.
Moreover, the availability of orphan products varied between
countries. The authors emphasize the importance of discussing
if orphan drugs should be placed in separated group for specific
reimbursement regulations to facilitate patient access.
Adkins et al. (2017) made a review to evaluate different
mechanisms that have been introduced to facilitate patient access
to oncologic orphan drugs in 5 different countries (Australia,
Canada, England, France, and Sweden), using 8 oncologic
orphan drugs and non-orphan oncologic drugs as examples
of their application. It was revealed that additional assessment
processes were rarely used and decisions were mostly driven
by proving cost-effectiveness using standard incremental cost-
effectiveness ratio thresholds. Application of standard HTA
criteria to oncologic orphan drugs in many countries does
not consider any specificity clinical and cost input producing
high cost-effectiveness results (above standard cost-effectiveness
thresholds) and HTA agencies should adopt a more flexible
approach to cost-effectiveness, considering high unmet medical
needs, limited clinical effectiveness evidence but also the small
patient numbers involved in therapy with orphan drugs.
A review by Zelei et al. (2016) focused on potentially relevant
value drivers in the reimbursement process of orphan drugs.
Due to external price referencing of pharmaceuticals, the relative
budget impact of orphan drugs is expected to be higher in
CEE than in Western European countries unless accessibility of
patients remains more limited in poorer European regions. Good
clinical evidence seems to play a fundamental role providing
an evidence for clinical effectiveness but also input to cost-
effectiveness analyzes, which play a key role in decision-making
in these countries.
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There were substantial differences in the total public
expenditure on orphan drugs per capita in participant countries.
The absolute spending was clearly associated with the economic
status of the countries. The generalizability of the findings may be
limited due to several reasons. It should be emphasized that the
orphan status of medicines is flexible and can change over time,
which considerably influenced the conclusions from the present
study compared with the previous results (Orphanet, 2018).
Although our study was planned and conducted so that it
was as reliable as possible, it is not free from limitations. First
of all, not all European countries were considered in the study
and this may introduce some selection bias. We considered
only those countries for which the required data were available
online. The results should be interpreted in the context of
analyzed countries and may not be generalizable to the EU
as a whole; however, the results can be generalizable to other
potential orphan drugs, which constitute the evident strength
of the study. In addition, the differences in decision-making
processes between the analyzed countries resulted in the lack of
data for recommendations for some of them.
Additionally, collection of data from different websites is
prone to errors hence there is a great need of the unified system
to bring together relevant data for reimbursed drugs for all EU
member states.
The κ coefficient with 95% CI was used to analyze the
agreement in reimbursement statuses between countries as well
as the agreement between reimbursement recommendations and
statuses within countries. To our knowledge, this is the best
approach; however, it could be influenced by the presence of bias
between countries and by the distributions of reimbursement
statuses. Hence, the presented coefficients should be treated as
descriptive statistics rather than an inference. The agreement as
well as predictive abilities of conditional approval and approval
under exceptional circumstances could be confounded by other
factors that were not analyzed in this study such as results of
economic analyzes, reliability of clinical trials of specific drugs,
or experts’ opinions.
Despite some limitations the study have several strengths:
a comprehensive analysis for eligible countries with different
reimbursement systems was performed, considering all orphan
drugs approved in the EU; it’s a novelty as no such studies
were conducted before. Results of the study would be useful
for reimbursement decision making and orphan drug policies in
European countries as international comparisons and review of
reimbursement statuses in other states could be an important
aspect providing simpler and faster evaluation of orphan drug
value. The results of this study should constitute a good basis for
further research.
CONCLUSIONS
The percentage of reimbursed orphan drugs varied among the
countries and was the lowest in Poland and the highest in
Denmark. The highest, substantial agreement in reimbursement
decisions was observed between Italy and Spain, and the
highest agreement in recommendations was observed between
England and Scotland. The conditional approval significantly
decreased the chance for reimbursement in France, Italy,
and Spain. The approval granted under the exceptional
circumstances had the same impact only in Germany. Drugs
for metabolic diseases were more likely to be approved under
exceptional circumstances, but had lesser odds for being
conditionally approved when compared to other drugs for
non-metabolic and non-oncologic diseases. The opposite was
observed for drugs used in treatment of patients with oncologic
diseases.
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APPENDIX—LIST OF REFERENCE WEBSITES
Poland (http://www.mz.gov.pl, http://www.aotm.gov.pl)
England (https://www.england.nhs.uk, https://www.nice.org.uk)
Scotland (http://www.isdscotland.org, https://www.scottishmedicines.org.uk)
Sweden (https://www.tlv.se)
Wales (www.wales.nhs.uk, http://www.awmsg.org)
Germany (https://www.dimdi.de, https://www.g-ba.de)
France (http://solidarites-sante.gouv.fr, https://www.has-sante.fr)
The Netherlands (https://www.gipdatabank.nl)
Denmark (http://www.medicinpriser.dk, https://laegemiddelstyrelsen.dk)
Belgium (http://www.inami.fgov.be)
Spain (https://www.vademecum.es)
Italy (http://www.aifa.gov.it)
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